6,10 G-protein-coupled receptors (GPCRs) are critically regulated by barrestins, which not only desensitize G-protein signalling but also initiate a G-protein-independent wave of signalling [1] [2] [3] [4] [5] . A recent surge of structural data on a number of GPCRs, including the b 2 adrenergic receptor (b 2 AR)-G-protein complex, has provided novel insights into the structural basis of receptor activation [6] [7] [8] [9] [10] [11] . However, complementary information has been lacking on the recruitment of b-arrestins to activated GPCRs, primarily owing to challenges in obtaining stable receptor-b-arrestin complexes for structural studies. Here we devised a strategy for forming and purifying a functional human b 2 AR-barrestin-1 complex that allowed us to visualize its architecture by single-particle negative-stain electron microscopy and to characterize the interactions between b 2 AR and b-arrestin 1 using hydrogendeuterium exchange mass spectrometry (HDX-MS) and chemical crosslinking. Electron microscopy two-dimensional averages and threedimensional reconstructions reveal bimodal binding of b-arrestin 1 to the b 2 AR, involving two separate sets of interactions, one with the phosphorylated carboxy terminus of the receptor and the other with its seven-transmembrane core. Areas of reduced HDX together with identification of crosslinked residues suggest engagement of the finger loop of b-arrestin 1 with the seven-transmembrane core of the receptor. In contrast, focal areas of raised HDX levels indicate regions of increased dynamics in both the N and C domains of barrestin 1 when coupled to the b 2 AR. A molecular model of the b 2 ARb-arrestin signalling complex was made by docking activated b-arrestin 1 and b 2 AR crystal structures into the electron microscopy map densities with constraints provided by HDX-MS and crosslinking, allowing us to obtain valuable insights into the overall architecture of a receptor-arrestin complex. The dynamic and structural information presented here provides a framework for better understanding the basis of GPCR regulation by arrestins.
G-protein-coupled receptors (GPCRs) are critically regulated by barrestins, which not only desensitize G-protein signalling but also initiate a G-protein-independent wave of signalling [1] [2] [3] [4] [5] . A recent surge of structural data on a number of GPCRs, including the b 2 adrenergic receptor (b 2 AR)-G-protein complex, has provided novel insights into the structural basis of receptor activation [6] [7] [8] [9] [10] [11] . However, complementary information has been lacking on the recruitment of b-arrestins to activated GPCRs, primarily owing to challenges in obtaining stable receptor-b-arrestin complexes for structural studies. Here we devised a strategy for forming and purifying a functional human b 2 AR-barrestin-1 complex that allowed us to visualize its architecture by single-particle negative-stain electron microscopy and to characterize the interactions between b 2 AR and b-arrestin 1 using hydrogendeuterium exchange mass spectrometry (HDX-MS) and chemical crosslinking. Electron microscopy two-dimensional averages and threedimensional reconstructions reveal bimodal binding of b-arrestin 1 to the b 2 AR, involving two separate sets of interactions, one with the phosphorylated carboxy terminus of the receptor and the other with its seven-transmembrane core. Areas of reduced HDX together with identification of crosslinked residues suggest engagement of the finger loop of b-arrestin 1 with the seven-transmembrane core of the receptor. In contrast, focal areas of raised HDX levels indicate regions of increased dynamics in both the N and C domains of barrestin 1 when coupled to the b 2 AR. A molecular model of the b 2 ARb-arrestin signalling complex was made by docking activated b-arrestin 1 and b 2 AR crystal structures into the electron microscopy map densities with constraints provided by HDX-MS and crosslinking, allowing us to obtain valuable insights into the overall architecture of a receptor-arrestin complex. The dynamic and structural information presented here provides a framework for better understanding the basis of GPCR regulation by arrestins.
To facilitate the isolation of a stable b 2 AR-b-arrestin complex, we used a modified b 2 AR construct with its C terminus replaced by that of the arginine vasopressin type 2 receptor (AVPR 2 ). This chimaeric receptor (b 2 V 2 R) maintains pharmacological properties identical to the b 2 AR, but it binds b-arrestins with higher affinity compared to wild-type b 2 AR 12 . We co-expressed b 2 V 2 R, b-arrestin 1 (1-393) and GRK2 CAAX (GRK2 with a membrane-tethering prenylation signal) in insect cells followed by agonist stimulation and affinity purification through the Flag-tagged receptor (Fig. 1a ) However, since the isolation of a stable complex was still not feasible ( Fig. 1b, lanes 1 and 2) , we explored enhancing its stability by adding Fab30, an antibody fragment we previously reported that selectively recognizes and stabilizes the active conformation of b-arrestin 1 (ref. 13) . Indeed, incubation of Fab30 with preformed complex in the membrane resulted in a robust purification of the b 2 V 2 R-b-arrestin-1 complex (Fig. 1b, lanes 5 and 6) , whereas a nonspecific Fab (referred to as Fab1) did not support complex stabilization (Fig. 1b, lanes 3 and 4) . Complex isolation was only possible in response to an agonist (BI-167107) and not an inverse agonist (ICI-118551) (Fig. 1b, lanes 5 and 6) . Furthermore, the efficiency of complex purification using this approach directly mirrors the pharmacological efficacy of the ligand used to stimulate the cells (Fig. 1c ). While stimulation of cells with inverse agonists does not yield detectable co-purification of b-arrestin 1, agonists robustly stabilize the complex and partial agonists yield co-purification of b-arrestin 1 at moderate levels. Moreover, the efficiency of complex formation also corresponds to the ligand occupancy of the receptor as reflected by the increasing amount of b-arrestin 1 co-purification with increasing agonist concentrations (Extended Data Fig. 1a, b ). The direct correlation of ligand efficacy and occupancy with purification efficiency reflects the fact that this approach yields a complex that depends on both activated receptor conformation and receptor phosphorylation. The purified b 2 V 2 R-b-arrestin-1-Fab30 complex also exhibited a robust interaction with the purified clathrin terminal domain compared to b-arrestin 1 alone, suggesting that b-arrestin 1 in this complex is in a physiologically relevant and functional conformation (Extended Data Fig. 2 ) [14] [15] [16] . Importantly, this strategy allowed preparative scale purification of a highly stable b 2 V 2 R-b-arrestin-1-Fab30 complex as assessed by analytical size exclusion chromatography (Fig. 1a , bottom right, green trace, and Extended Data Fig. 1c ). In addition to the Fab30-stabilized b 2 V 2 R-b-arrestin-1 complex, we were also able to obtain equally stable b 2 V 2 R-b-arrestin-1 complexes using the singlechain variable fragment of Fab30 (ScFv30) (Fig. 1a , bottom right, blue trace).
The interaction of b-arrestins with activated GPCRs is proposed to involve two sequential steps 17 . First, the phosphorylated C terminus of activated GPCRs is thought to engage the N domain of b-arrestins, a high-affinity charge-charge interaction primarily mediated between the phosphates on the receptor tail and basic residues on b-arrestins 13, 17 . This first engagement is hypothesized to facilitate activating conformational changes in b-arrestin, leading in turn to additional interactions with the transmembrane core of the receptor 17 . To obtain dynamic structural information on the receptor-b-arrestin complex, we carried out HDX-MS analysis on the purified assembly 18, 19 . In addition to the b 2 V 2 R-b-arrestin-1-Fab30 complex, we used the AVPR 2 C-terminal phosphopeptide (V 2 Rpp)-b-arrestin-1-Fab30 complex as a reference to extract specific information about the core interaction between the receptor and b-arrestin 1.
We observed a reduction in the HDX rate in the three major loopsthe finger loop (55%), the middle loop (16%) and the lariat loop (23%)-of b-arrestin 1 when we compared the HDX-MS profile of the b 2 V 2 R-b-arrestin-1-Fab30 complex with that of the V 2 Rpp-b-arrestin-1-Fab30 complex ( Fig. 2 and Extended Data Fig. 3a ). Thus, these regions, and especially the finger loop, are likely to be buried (or have reduced solvent exposure) in the b 2 V 2 R-b-arrestin-1-Fab30 complex, probably through an intricate engagement with the transmembrane receptor core. This finding is consistent with previous electron paramagnetic resonance (EPR) studies on rhodopsin-arrestin interactions, which revealed a crucial involvement of the finger loop of arrestin with the core of rhodopsin 17, [20] [21] [22] . Interestingly, several regions in both the N and the C domains of b-arrestin 1, in contrast, reveal enhanced HDX rates, indicating that they become more dynamic upon interaction of b-arrestin with the agonist-bound phosphorylated receptor. This observation suggests that the core interaction between b-arrestin 1 and b 2 V 2 R probably has long-range effects on b-arrestin 1 structure. Previous studies mapping interactions between GPCRs and arrestins suggested that receptors may also interact with the broad concave surfaces of the N and C domains of arrestins 21, [23] [24] [25] . However, peptides representing these surfaces are not fully represented in our HDX-MS studies, thus limiting our ability to detect these interactions. We also note that our previously published high-affinity agonist radioligand binding data on the T4 lysozyme (T4L)-b 2 V 2 R-b-arrestin-1-Fab30 complex in membranes, which provides a readout of the fully engaged b-arrestin conformation, suggested that approximately 32% of the receptor is in a high-affinity agonist binding state 13 . This indicates that our HDX-MS data represent an average of two mixed complex populations, one with fully engaged b-arrestin 1 with the receptor and the other displaying partially engaged b-arrestin 1.
Our previous crystal structure of V 2 Rpp bound to activated barrestin 1 revealed a marked repositioning of the finger loop compared to when it is bound to the inactive b-arrestin 1, presumably because it is primed to engage with the transmembrane core of the activated receptor 13 . To test this we carried out MS-based mapping of the T4Lb 2 V 2 R-b-arrestin-1 interface using the homobifunctional, primary amine reactive chemical crosslinker disuccinimidyl adipate (DSA). We found that Lys 77 on b-arrestin 1 (towards the distal end of the finger loop) crosslinks with Lys 235 in the third intracellular loop of the b 2 AR (Extended Data Fig. 3b-e ). These findings are in line with previously published biochemical and biophysical data suggesting an intricate interaction of the receptor core and the finger loop in arrestins. As an additional control for the close proximity of these residues, we created a series of mutants with single cysteine substitutions around Lys 235 in the Nterminal end of the third intracellular loop of the b 2 V 2 R (amino acids 231-236) and in the finger loop around Lys 77 of b-arrestin 1 (amino acids 75-79) and evaluated the formation of disulphide-trapped complexes in pairs of receptor and b-arrestin-1 mutants. Consistent with our chemical crosslinking data, cysteines engineered at position 235 of the receptor and at position 78 in b-arrestin 1 yielded the most robust disulphide-trapped complex, suggesting a close proximity of these two residues in the complex (Extended Data Fig. 4 ). Taken together these findings demonstrate a direct interaction of the finger loop with the receptor core.
We next employed single-particle electron microscopy (EM) to examine the architecture and conformational dynamics of b 2 V 2 R-b-arrestin-1 complexes. Owing to the asymmetric nature and small size of these complexes (,150 kilodalton (kDa) and ,125 kDa for the Fab and ScFv complexes, respectively) characterization attempts with cryo-EM were 
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not successful and we thus applied negative-stain EM, which provides adequate contrast for alignment of small particle projections. This approach also enabled a direct comparison with our earlier negativestain EM analysis of the b 2 AR-Gas protein complex 9 . As in that work, here we used a T4L fusion at the N terminus of the receptor (referred to as T4L-b 2 V 2 R) to provide a marker for the receptor orientation 9 . The negative-stain EM visualization showed a monodisperse particle population ( Fig. 3a and Extended Data Fig. 5 ) and we applied referencefree alignment and classification to obtain two-dimensional averages of the complex.
The majority of averages of the b 2 V 2 R-b-arrestin-1-Fab30 complex revealed distinct projection profiles of an ovoid density, attributed to the receptor in partially flattened detergent micelle, with an attached T-like density attributed to the Fab30-b-arrestin-1 complex ( Fig. 3b and Extended Data Fig. 6a ). Comparisons with averages of the b 2 V 2 R-barrestin-1-ScFv30 complex identify the Fab30 density engaging the middle of b-arrestin 1, in agreement with our recent crystal structure of b-arrestin-1-Fab30 co-crystallized with the V 2 Rpp (Fig. 3b and Extended Data Fig. 6b ). In this conformation b-arrestin 1 appears to hang off the receptor via a single point interaction presumably involving only the flexible V 2 Rpp fused on b 2 AR. The flexible nature of this interaction is further supported by the variable receptor orientation in these averages, as judged by the T4L domain positioning. It is possible that this 'hanging' arrestin conformation based on the V 2 Rpp-b-arrestin-1 interaction represents a transient intermediate step in the recruitment process that has been stabilized by Fab30. Strikingly, we also observe a substantial number of class averages, representing ,37% of particles, in which b-arrestin 1 forms a much more extensive interface with the receptor, employing roughly the opposite face of the Fab30 binding region (Fig. 3b, bottom) . The observed fraction of particles displaying the extensive interface is in agreement with our previous radioligand binding results on the T4L-b 2 V 2 R-b-arrestin-1-Fab30 complex in membranes, which suggested that approximately 32% of the receptor is in a high-affinity agonist binding state 13 . This observation also raised the possibility that b-arrestin 1 fully engages the receptor through a second set of weak interactions.
To stabilize this weak interaction, we developed an approach whereby the b 2 V 2 R-b-arrestin-1-Fab30/ScFv30 complex is crosslinked by exposure to a glutaraldehyde-containing buffer zone while migrating through a size exclusion column (Extended Data Fig. 7a ). This method facilitated near complete crosslinking of preformed complexes at relatively high concentrations and simultaneously enabled the isolation of highly monodisperse sample (Extended Data Figs 7b, c, 8, 9) .
EM classification and averaging of the crosslinked b 2 V 2 R-b-arrestin-1-Fab30/ScFv30 complexes revealed distinct views of a uniform particle architecture, suggesting that crosslinking stabilized a single complex conformer ( Fig. 3c ). More importantly, the averages show that arrestin interacts extensively with the receptor in a configuration that appears very similar to the one observed in the smaller fraction (,37%) of the RESEARCH LETTER native complex. The conformational stabilizing action of the crosslinking is also evidenced by the consistent position of the T4L projection profile, in contrast to the variable positioning observed in averages of the native complex. To better characterize the b 2 V 2 R-b-arrestin-1 assembly, we employed the random conical-tilt approach 26 to calculate lowresolution three-dimensional maps (,29 Å ) from selected classes of the crosslinked complex (Extended Data Fig. 10 ). The three-dimensional reconstructions show distinct densities for the main complex components, in full agreement with our domain assignment in the two-dimensional projections averages ( Fig. 4a and Extended Data Fig. 10 ). The receptorcontaining region appears ovoid due to the large micelle 'belt' characteristic of the lauryl maltose neopentyl glycol (LMNG) detergent, as we also observed in the case of the b 2 AR-Gas complex 9 . A protrusion on one end of the receptor-micelle globular density represents the T4L domain that marks the receptor extracellular region. On the opposite side, the b-arrestin 1 density lies longitudinally on the receptor, engaging roughly the opposite side of the Fab30-interacting region. In this configuration, both b-arrestin domains appear to engage the receptor but one of the domains lies mostly outside the interacting zone. The HDX-MS, chemical crosslinking and disulphide trapping data allowed us to constrain the modelling of the T4L-b 2 AR and b-arrestin-1-Fab30 crystal structures within the density of the EM three-dimensional maps and generate a low-resolution model for the overall conformation of the b 2 AR-b-arrestin-1 complex (Fig. 4b ). This model can accommodate limited rotations and translations of the individual crystal structures, which are also expected to undergo conformational changes upon complex formation. Lys 77 of b-arrestin 1 in our model is placed in close proximity to b 2 AR Lys 235, which is located at the end of a helical extension of transmembrane (TM)5 in the b 2 AR-Ga s complex 10 . This prompted us to use this structure to model the b 2 AR-b-arrestin-1 complex. In our model, b-arrestin 1 forms an extensive interface with the receptor through its N-terminal domain, which includes interactions with the phosphorylated receptor tail and the insertion of the finger loop directly in the receptor core, involving the space between TM3, 5 and 6. We note that the finger loop insertion is probably associated with outward shifts in the positioning of TM helices 3, 5 and 6 and also helix 8. The middle and lariat loops of b-arrestin 1 do not participate in major interactions but reside close to the interface, as suggested by the modest reduction in their HDX rates observed by HDX-MS (Fig. 2c) . The relative positioning of these loops is also in agreement with previous EPR studies on visual arrestin in complex with activated and phosphorylated rhodopsin 20, 21 .
In 
b-arrestin 1. The placement of these receptor elements implies that the N terminus of V 2 Rpp cannot be in the position observed in the crystal structure of V 2 Rpp-b-arrestin-1-Fab30 (ref. 13 ), suggesting that the V 2 R C terminus in the b 2 V 2 R chimaeric receptor is mobile and repositions itself markedly upon b-arrestin-1 interaction with the receptor core. In contrast to the N-terminal domain, the C-terminal domain of b-arrestin 1 lies mostly outside the interaction zone, apart from the loop of residues 242-246 that is at interacting distance from the short a-helical segment connecting TM3 and TM4 of b 2 V 2 R. This observation is intriguing considering that mutation of the residues distal to the DRY motif (at the end of TM3) have been reported to directly affect b-arrestin recruitment for a number of GPCRs including the b 2 AR 27 .
Our results suggest that arrestin probably employs a biphasic mechanism to engage the receptor (Fig. 4c ). The first phase involves an interaction between the phosphorylated C-terminal tail of the receptor and the N-terminal domain of arrestin. Given the flexibility and the length of the C-terminal receptor tail, it is expected to act like a fishing line, sampling a wide interaction space at a high rate. The second point of interaction appears weak and involves primarily the insertion of the finger loop within the receptor core, resulting in a longitudinal arrangement of arrestin on the receptor (Fig. 4a, c) . This arrangement would most certainly preclude GPCR engagement of G-protein heterotrimers, thereby blocking classical GPCR signalling and inducing desensitization. While it is not yet clear whether the single point interaction resulting in a hanging arrestin configuration has other physiological functions, it seems possible that these might involve recruitment and complex formation with components of the receptor endocytosis and signalling machinery such as clathrin and Gbc.
METHODS SUMMARY
b 2 V 2 R, b-arrestin 1 and GRK2 CAAX were co-expressed in Sf9 cells. Sixty-six hours post-infection, cells were stimulated with the high-affinity agonist BI-167107 for 30 min at 37 uC. Cells were harvested and lysed by douncing, followed by incubation with purified Fab30. One hour post-incubation, cells were solubilized and purified on a Flag M1 affinity column followed by size exclusion chromatography. The purified complex was subjected to HDX-MS analysis by incubating it with D 2 O for various time points followed by pepsin digestion and liquid chromatography (LC)/ MS-based identification of peptides. Purified T4L-b 2 V 2 R-b-arrestin-1-Fab30/ScFv30 complex was embedded in negative stain and visualized by EM. EM two-dimensional averages of the complexes were obtained by ISAC 28 and three-dimensional reconstructions were obtained through the random conical-tilt method 26 .
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METHODS
Reagents. Insect cell culture media and transfection kits to generate various virus stocks were purchased from Expression Systems. Superdex 200 SEC columns were purchased from GE healthcare and detergents were purchased from Anatrace. EMgrade glutaraldehyde solution and other general chemicals were purchased from Sigma. Protein expression and purification. T4L-b 2 V 2 R plasmid (with N-terminal fusion of T4L) was generated by modifying the previously described T4L-b 2 AR plasmid 6 . T4L-b 2 V 2 R was co-expressed with untagged bovine b-arrestin 1 (1-393) and untagged GRK2 CAAX in Sf9 cells. Sixty-to-sixty-six hours post-infection, cells were stimulated for 30 min (or the indicated time) at 37 uC with the indicated ligand to induce receptor phosphorylation and ternary complex formation. Subsequently, cells were harvested, lysed in 20 mM HEPES, pH 7.4, 150 mM NaCl, 100 nM-1 mM ligand and protease inhibitors by douncing and purified Fab30/ScFv30 was added to this cell lysate. Following 1 h incubation at room temperature, proteins were solubilized by adding detergent (0.5% LMNG or 1% dodecyl maltoside (DDM)) and underwent gentle stirring at room temperature for 1 h. Solubilized material was purified on a Flag M1 resin essentially using the protocol described for b 2 AR purification previously 11 . In order to avoid potential protein aggregation at high concentration, free cysteines in the eluted proteins were blocked using iodoacetamide as described previously 11 . Proteins were concentrated using a 100 kDa cut-off Vivaspin or Millipore concentrator and loaded on to a preparative size exclusion column (Superdex 200, 16/ 600). The column was run at 0.3 ml min 21 and the column running buffer consists of 20 mM HEPES, pH 7.4, 150 mM NaCl, 100 nM BI-167107, 0.01% LMNG, 100 mM TCEP. Elution fractions corresponding to the complex peak were either pooled or used individually for further studies. Selection, characterization and purification of this Fab30 have been described previously 13 . Biochemical and functional characterization of the complex. In order to pharmacologically validate this novel procedure, we stimulated the cells with multiple ligands (10 mM) of varying efficacies (ranging from inverse agonists, partial agonists to full agonists). Subsequently, the cells were lysed, incubated with Fab30 and the complex was purified using Flag M1 affinity resin. Purification of complex was assessed by the extent of b-arrestin 1 co-purified with the receptor. In order to further investigate agonist dependence of the complex formation, we assessed whether formation of this ternary complex through Fab30 stabilization follows ligand occupancy of the receptor. Cells were stimulated with varying doses of the agonist BI-167107 or inverse agonist ICI-118551 at 37 uC for 30 min. Subsequently, purification of the complex was performed as described earlier. Similarly, a time course of agonist and inverse agonist stimulation was carried out to identify the optimal time point to achieve maximal complex formation.
For stability analysis, the purified T4L-b 2 V 2 R-b-arrestin-1-Fab30 complex (1 mg ml 21 ) was either analysed fresh after purification (reference sample, day 0) or incubated in the cold room and at room temperature for 4 days. Subsequently, the samples were analysed by analytical size exclusion chromatography using a Superdex 200 (10/300) column. The column was run at 0.3 ml min 21 and the column running buffer consists of 20 mM HEPES, pH 7.4, 150 mM NaCl, 100 nM BI-167107, 0.01% LMNG, 100 mM TCEP.
In order to validate the active conformation of b-arrestin 1 in the T4L-b 2 V 2 Rb-arrestin-1-Fab30 complex, we evaluated the ability of this complex to interact with purified clathrin terminal domain (TD) (heavy chain). The GST-clathrin-TD expression plasmid was a gift from J. Benovic and D. Kang. GST-clathrin-TD was expressed in Escherichia coli using a previously published procedure 29 and immobilized on glutathione sepharose beads. Subsequently, either the purified complex (in 20 mM HEPES, 150 mM NaCl, 0.01% LMNG, 100 nM BI-167107) or purified b-arrestin 1 (1-393) was added to the clathrin-TD and incubated at room temperature for 1 h. The amount of complex used in this experiment was normalized to contain equivalent amount of b-arrestin 1 as in the b-arrestin 1 alone sample in order to directly compare the extent of clathrin interaction. Subsequently, the beads were washed three times with the same buffer as described earlier and proteins were eluted using the SDS-gel loading buffer. The samples were analysed by western blotting using anti-b-arrestin 1 antibody and anti-clathrin antibody (BD Biosciences). Conversion of Fab30 in to ScFv30. In order to convert the Fab30 into an ScFv, the variable domains of the light chain and the heavy chain were joined through a flexible linker (GTTAASGSSGGSSSGA) using standard PCR amplification and cloning techniques. The resulting sequence of the ScFv30 is as follows (linker sequence is highlighted in bold): MKKNIAFLLASMFVFSIATNAYASDIQMTQSPSSLSAS VGDRVTITCRASQSVSSAVAWYQQKPGKAPKLLIYSASSLYSGVPSRFSGSRS GTDFTLTISSLQPEDFATYYCQQYKYVPVTFGQGTKVEIKGTTAASGSSGG SSSGAEVQLVESGGGLVQPGGSLRLSCAASGFNVYSSSIHWVRQAPGKGLE WVASISSYYGYTYYADSVKGRFTISADTSKNTAYLQMNSXRAEDTAVYYCA RSRQFWYSGLDYWGQGTLVTVSSAHHHHHH.
ScFv30 was expressed using the same protocol as Fab30. It was either purified on Ni-NTA resin or used directly as periplasmic extract to stabilize the T4L-b 2 V 2 Rb-arrestin-1 complex. Glutaraldehyde crosslinking of the preformed complex. In order to mildly crosslink the complex, an 'on-column' crosslinking method was used. First, a bolus of glutaraldehyde was injected to a pre-equilibrated Superdex 200 (10/300 global in 20 mM HEPES, pH 7.4, 150 mM NaCl, 0.01% LMNG, 100 nM BI-167107) column and run at 0.25 ml min 21 for 20 min (that is, a total of 5 ml buffer). Subsequently, the column flow was paused, and the injection loop was flushed using buffer followed by injection of purified complex (200 ml volume, at 5-10 mM concentration). Subsequently, the column was run at 0.25 ml min 21 and 0.3 ml fractions were collected. Crosslinking efficiency was visualized by running the individual fractions on a 4-20% SDS gel, followed by staining with 'SimplyBlue' stain. Various concentrations of glutaraldehyde were tested in order to identify an optimal concentration (0.25% in this case) that yields maximal crosslinking efficiency and minimal protein aggregation. HDX-MS Fragmentation tuning for b-arrestin 1. We first performed fragmentation tuning experiments in order to optimize experimental conditions to achieve the best peptide fragmentation pattern for b-arrestin 1. In brief, 3 ml of b-arrestin 1 protein solution was diluted with 9 ml of a buffer containing 150 mM NaCl, 8.3 mM Tris-HCl, pH 7.2 in H 2 O and then divided into equal sized aliquots. Each aliquot was mixed individually with 18 ml of a series of quench solutions containing 0.8% formic acid, 16.6% glycerol, and various concentrations of GuHCl (ranging from 0.05 to 4 M) and TCEP (ranging from 0.015 to 0.5 M). The protein-buffer-quench solution mixtures were incubated at 0 uC for 1 min, frozen on dry ice and then stored at 280 uC until subjected to on-line pepsin digestion and liquid chromatography (LC)/MS analysis. Protein fragmentation maps under different conditions were generated and compared. The condition that produced the best peptide fragmentation pattern (the best coverage along the amino acid sequence, the most number of fragments, and highest number of high quality peptides) was used for all the HDX-MS experiments described in this study. HDX experiments. The V 2 Rpp-b-arrestin-1-Fab30 and T4L-b 2 V 2 R-b-arrestin-1-Fab30 complexes were prepared as described earlier. Free b-arrestin 1 protein was used as a control. For each protein complex, three sets of samples were prepared: at 0 uC and incubating for varying time points (10 s, 10 2 s, 10 3 s, 10 4 s and 10 5 s). Six volumes of ice-cold quench solution was then added to each sample, followed by snap-freezing on dry ice and storage at 280 uC. On-line pepsin digestion, LC/MS analysis and data processing. Samples prepared as described earlier were thawed right before the on-line pepsin digestion at 0 uC using a cryogenic autosampler and immediately passed over an immobilized porcine pepsin column (16 ml bed volume). Peptide fragments were collected contemporaneously on a C 18 trap desalting column, separated by a Magic C 18 AQ column using a linear gradient of acetonitrile from 6.4 to 38.4% over 30 min, and followed by LC/MS analysis using an Orbitrap Elite mass spectrometer (Thermo Scientific). Both MS1 and MS2 spectra were collected using the data-dependent acquisition mode. Peptide identification was performed using LC/MS data sets collected from ND samples and the SEQUEST database search engine using Proteome Discoverer (Thermo Fisher Scientific). The SEQUEST database search results were submitted to DXMS Explorer (version 2.0, Sierra Analytics), filtered using several threshold parameters to create an initial peptide pool. The quality of the MS1 data for each filtered peptide was then checked by assigning an initial quality score by DXMS Explorer software, followed by a quality control process which included manual investigation of peak isotopic envelope and adjusting/improving the quality score. Only peptides with high quality in the MS1 spectra were kept in the final peptide pool. The retention times and m/z ranges of each peptide from the final peptide pool was manually verified and adjusted across all LC/MS data sets from onexchange samples and FD samples to ensure that DXMS Explorer had selected the correct peptide for all experiments. Results from FD samples were used to monitor the back-exchange rates during on-line pepsin digestion and LC/MS analysis. The centroids of isotopic envelopes of non-deuterated, partially deuterated and fully deuterated peptides were measured using DXMS Explorer, and then converted to deuteration level with corrections for back-exchange. A deuterium accumulation plot was created for each peptide as a further quality check and data refinement LETTER RESEARCH process. Rainbow maps were generated and DXMS data comparison was performed using different macros in Excel. Chemical crosslinking and mass spectrometry Chemical crosslinking reaction. In order to identify a potential interaction interface between the b 2 V 2 R and b-arrestin 1, we performed chemical crosslinking experiments on the preformed T4L-b 2 V 2 R-b-arrestin-1-Fab30 complex. To facilitate the identification of crosslinked peptides, we used an equimolar mixture of light ( 12 C6) and heavy ( 13 C6) DSA (a homobifunctional amine-reactive crosslinker, spacer arm 5 8.6 Å ) to crosslink the complex. The crosslinked peptides were characterized with 'doublet' peak signatures in mass spectra. The T4L-b 2 V 2 R-b-arrestin-1-Fab30 complex was prepared in buffer containing 20 mM HEPES, 150 mM NaCl, 0.01% LMNG, 100 nM BI, 100 mM TCEP. Crosslinker solution was freshly prepared in DMSO at a concentration of 10 mM. For the crosslinking reaction, 100-fold excess of DSA-12 C6:DSA-13 C6 equimolar mixture was added to the T4L-b 2 V 2 Rb-arrestin-1-Fab30 complex solution and incubated for 30 min at 25 uC. Unreacted crosslinker was quenched by incubation with 100 mM ammonium bicarbonate for 20 min. The crosslinked T4L-b 2 V 2 R-b-arrestin-1-Fab30 complex was separated by SDS-PAGE, and the corresponding protein band was in-gel digested overnight at 37 uC with trypsin at a final concentration of 10 ng ml 21 and subjected to LC/MS analysis. LC/MS analysis and crosslinked peptide identification. LC/MS analyses were performed on a LTQ Orbitrap XL mass spectrometer (Thermo Scientific) with a Finnigan Nanospray II electrospray ionization source. Tryptic peptides were injected onto a 75 mm 3 150 mm BEH C18 column (particle size 1.7 mm, Waters) and separated using a Waters nano ACQUITY Ultra Performance LC (UPLC) System. The LTQ Orbitrap XL was operated in the data dependent mode using the TOP10 strategy 30 . In brief, each scan cycle was initiated with a full MS scan of high mass accuracy 375-1,800 m/z, acquired in the Orbitrap XL at 6 3 10 4 resolution setting and automatic gain control (AGC) target of 10 6 , which was followed by MS/MS scans (AGC target 5,000; threshold 3,000) in the linear ion trap on the ten most abundant precursor ions. Selected ions were dynamically excluded for 30 s. Singly charged ions were excluded from MS/MS analysis. The LC/MS/MS data were processed and analysed by pLink software 31 . In brief, acquired raw data from LTQ Orbitrap XL mass spectrometer were first converted to mgf files using Mascot Distiller or Proteowizard 3.0 and saved under a pLink master directory, where a composite database containing protein sequences of T4L-b 2 V 2 R, b-arrestin 1 and Fab30 in FASTA format is also stored. In the pLink configuration file, both the names and paths of the mgf and database file were indicated correspondingly. The total numbers of fixed modifications was set to 1 for cysteine carbamidomethylation. The name and number of crosslinkers used in the experiment were indicated as well in the configuration file. The filter for precursor mass accuracy was set to 6 10 p.p.m. After pLink analysis, identified crosslinked peptides were manually inspected in the raw file for the appearance of a pair of doublet MS peaks. Disulphide trapping of b 2 V 2 R and b-arrestin-1 complex. Cysteine mutants of the b 2 V 2 R and b-arrestin 1 were co-expresed in HEK-293 cells. Forty-eight hours post-transfection, cells were stimulated with the b 2 AR agonist isoproterenol (10 mM) and treated with H 2 O 2 (1 mM) at different time points to induce the formation of disulphide bond and trap the complex. Cells were washed and lysed in lysis buffer (50 mM HEPES, 250 mM NaCl, pH 7.4, 2 mM EDTA, 10% glycerol, 0.5% NP40, 1 mM NaV, 57 mM NaF, EDTA-free complete protease inhibitor). Cell lysates were used for anti-Flag antibody immunoprecipitation (N-terminal Flag-tagged b 2 V 2 ). Beads were washed and eluted proteins were separated by SDS-PAGE followed by detection using western blotting. Expression levels of the receptor and b-arrestin-1 mutants were measured by radioligand binding and western blotting, respectively. Densitometry analysis of the b-arrestin-1 bands was done using ImageJ software. Specimen preparation and EM imaging of negative-stained samples. T4Lb 2 V 2 R-b-arrestin-1-Fab30/ScFv30 complex was prepared for EM using the conventional negative-staining protocol 32 , and imaged at room temperature with a Tecnai T12 electron microscope operated at 120 kV using low-dose procedures. Images were recorded at a magnification of 371,138 and a defocus value of ,1.5 mm on a Gatan US4000 CCD camera. All images were binned (2 3 2 pixels) to obtain a pixel size of 4.16 Å on the specimen level. Particles were manually excised using Boxer (part of the EMAN 1.9 software suite) 33 apart from tilt pairs (0u and 60u) where particles were selected using WEB 34 . Two-dimensional classification and three-dimensional EM reconstructions. Two-dimensional reference-free alignment and classification of particle projections was performed using ISAC 28 . Sixteen-thousand two-hundred and eighty-six 0u particle projections of native T4L-b 2 V 2 R-b-arrestin-1-Fab30 complex and 13,703 0u projections of native T4L-b 2 V 2 R-b-arrestin-1-ScFv30 complex were subjected to ISAC, producing 186 classes accounting for 9,193 particle projections and 145 classes accounting for 8,127 projections, respectively. Fourteen-thousand one-hundred and nine 0u particle projections of crosslinked T4L-b 2 V 2 R-b-arrestin-1-ScFv30 complex and 13,106 0u projections of crosslinked T4L-b 2 V 2 R-b-arrestin-1-Fab30 complex were subjected to ISAC, producing 111 classes accounting for 8,011 particle projections and 149 classes accounting for 8,127 projections, respectively. To determine the particle distribution of native T4L-b 2 V 2 R-b-arrestin-1-Fab30 conformations, each class average was designated as 'tight', 'loose' or 'unassigned' and the number of projections contributing to the class averages for each designation were added to calculate percentages.
For native and crosslinked Fab30 complexes the random conical tilt technique 26 was used to calculate a first back projection map from individual classes using the 60u tilted particle projections. After angular refinement of the 60u projections, untilted particle projections were added to the data set and the images were subjected to another cycle of refinement. For final reconstructions, particle projections from similar class averages were pooled together, corrected for contrast transfer function (CTF) according to local defocus values obtained by CTFTILT 35 and subjected to further angular refinement and reconstruction in FREALIGN 36 . Twothousand eight-hundred and twenty-five particle projections from 0u and 60u images contributed to the crosslinked T4L-b 2 V 2 R-b-arrestin-1-Fab30 complex reconstruction. Two-thousand one-hundred and ninety-six particle projections from 0u and 60u images contributed to the native T4L-b 2 V 2 R-b-arrestin-1-Fab30 threedimensional reconstruction. The resolution for each map was determined by the conventional Fourier shell correlation (FSC) approach at FSC 5 0.5 (Extended Data Fig. 10 ). Molecular modelling. For modelling the T4L-b 2 V 2 R-b-arrestin-1-Fab30 complex we used the crystal structure of T4L-b 2 AR from the T4L-b 2 AR-Gas complex (PDB accession 3SN6) 6 and the crystal structure of V 2 Rpp-b-arrestin-1-Fab30 (PDB accession 4JQI). Owing to the low resolution of the EM map and the presence of the considerable detergent micelle density surrounding the receptor region, all docking operations within the EM maps were performed manually with visual inspection of best fit while taking into account additional constraints from crosslinking and HDX-MS data. The Fab30 and T4L structures were independently shifted from the original position in the corresponding crystal structures to obtain an improved fit into the EM density map, reflecting both the flexible nature of their association with b-arrestin 1 and b 2 AR, respectively, and a partial deformation of the complex on the carbon support of the EM grid. complex follows agonist occupancy of the receptor and is biochemically stable. a, Sf9 cells co-expressing the b 2 V 2 R, b-arrestin 1 (barr1) and GRK2 CAAX were stimulated with varying doses of the high-affinity agonist BI-167107 followed by addition of Fab30 and purification of the complexes. Stimulation of cells with increasing concentration of BI-167107 results in increasing amount of b-arrestin 1 co-purification, indicating a direct correlation between occupancy of the receptor with agonist and complex formation. b, Quantification of agonist-dependent complex formation from seven independent experiments normalized with respect to the b-arrestin-1 signal at the highest agonist concentration. c, Purified T4L-b 2 V 2 R-b-arrestin-1-Fab30 complex was stored either at 4 uC or at room temperature for 4 days followed by size exclusion chromatography on a Superdex 200 (10/300) column (flow rate 0.5 ml min 21 ) . No substantial dissociation of the complex was detected as monitored by appearance of a peak corresponding to the receptor (13.5 ml) or b-arrestin 1 (14.5 ml).
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